Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2002 1
2003 2
2006 1
2009 1
2011 1
2012 1
2013 2
2014 1
2015 1
2016 3
2017 1
2018 2
2019 1
2020 1
2022 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Flaherty KR, et al. N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. N Engl J Med. 2019. PMID: 31566307 Clinical Trial.
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Wells AU, et al. Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.
Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases.
Kawano-Dourado L, Kulkarni T, Ryerson CJ, Rivera-Ortega P, Baldi BG, Chaudhuri N, Funke-Chambour M, Hoffmann-Vold AM, Johannson KA, Khor YH, Montesi SB, Piccari L, Prosch H, Molina-Molina M, Sellares Torres J, Bauer-Ventura I, Rajan S, Jacob J, Richards D, Spencer LG, Wendelberger B, Jensen T, Quintana M, Kreuter M, Gordon AC, Martinez FJ, Kaminski N, Cornelius V, Lewis R, Adams W, Jenkins G; REMAP-ILD consortium. Kawano-Dourado L, et al. Thorax. 2024 Mar 6:thorax-2023-221148. doi: 10.1136/thorax-2023-221148. Online ahead of print. Thorax. 2024. PMID: 38448221 Free article. Review.
Sarcoidosis following alemtuzumab treatment for multiple sclerosis.
Willis MD, Hope-Gill B, Flood-Page P, Joseph F, Needham E, Jones J, Coles A, Robertson NP. Willis MD, et al. Among authors: hope gill b. Mult Scler. 2018 Nov;24(13):1779-1782. doi: 10.1177/1352458518790391. Epub 2018 Oct 11. Mult Scler. 2018. PMID: 30307364
Man and woman flu.
Healy B, Barnes R, Hope-Gill B, Ramanujam S, Baboolal K. Healy B, et al. Among authors: hope gill b. Br J Hosp Med (Lond). 2006 Dec;67(12):668-9. doi: 10.12968/hmed.2006.67.12.22443. Br J Hosp Med (Lond). 2006. PMID: 17328455 No abstract available.
22 results